130 related articles for article (PubMed ID: 38450787)
1. Implementation of PSMA PET/CT and alignment of ordering to SNMMI appropriate use criteria in a large network system.
Bennett R; Li EV; Ho AY; Aguiar JA; Neill C; Rowe SP; Patel HD; Savas H; Ross AE
Prostate; 2024 Jun; 84(8):717-722. PubMed ID: 38450787
[TBL] [Abstract][Full Text] [Related]
2.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
3. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
4. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
Kabasakal L; Demirci E; Nematyazar J; Akyel R; Razavi B; Ocak M; Aygun A; Obek C; Kural AR
Nucl Med Commun; 2017 Feb; 38(2):149-155. PubMed ID: 27893589
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
Lenis AT; Pooli A; Lec PM; Sadun TY; Johnson DC; Lebacle C; Fendler WP; Eiber M; Czernin J; Reiter RE; Calais J
Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
[TBL] [Abstract][Full Text] [Related]
6. Whole-Body Integrated [
Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
[TBL] [Abstract][Full Text] [Related]
7. Prostate-Specific Membrane Antigen PET/CT Combined with Sentinel Node Biopsy for Primary Lymph Node Staging in Prostate Cancer.
Hinsenveld FJ; Wit EMK; van Leeuwen PJ; Brouwer OR; Donswijk ML; Tillier CN; Vegt E; van Muilekom E; van Oosterom MN; van Leeuwen FWB; van der Poel HG
J Nucl Med; 2020 Apr; 61(4):540-545. PubMed ID: 31562222
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study.
Donswijk ML; van Leeuwen PJ; Vegt E; Cheung Z; Heijmink SWTPJ; van der Poel HG; Stokkel MPM
BMC Cancer; 2020 Aug; 20(1):723. PubMed ID: 32758168
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.
Xiang M; Ma TM; Savjani R; Pollom EL; Karnes RJ; Grogan T; Wong JK; Motterle G; Tosoian JJ; Trock BJ; Klein EA; Stish BJ; Dess RT; Spratt DE; Pilar A; Reddy C; Levin-Epstein R; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Huland H; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Alam R; Schwen Z; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Boutros PC; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Chong N; Kupelian PA; Rettig MB; Zaorsky NG; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Horwitz EM; Tendulkar RD; Tilki D; Czernin J; Gafita A; Romero T; Calais J; Kishan AU
JAMA Netw Open; 2021 Dec; 4(12):e2138550. PubMed ID: 34902034
[TBL] [Abstract][Full Text] [Related]
11. Is there a nonnegligible effect of maximum standardized uptake value in the staging and management of prostate cancer with 68Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography imaging? A single-center experience.
Ekmekcioglu O; Yavuzsan AH; Arican P; Kirecci SL
J Cancer Res Ther; 2021; 17(6):1351-1357. PubMed ID: 34916365
[TBL] [Abstract][Full Text] [Related]
12. Establishment and prospective validation of an SUV
Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
[No Abstract] [Full Text] [Related]
13. A Prospective Comparison of
Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
[TBL] [Abstract][Full Text] [Related]
14. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre.
Haran C; McBean R; Parsons R; Wong D
J Med Imaging Radiat Oncol; 2019 Aug; 63(4):495-499. PubMed ID: 30972933
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific membrane antigen PET/computed tomography for staging prostate cancer.
Ravi Kumar AS; Lawrentschuk N; Hofman MS
Curr Opin Urol; 2020 Sep; 30(5):628-634. PubMed ID: 32701720
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
Meijer D; Eppinga WSC; Mohede RM; Vanneste BGL; Meijnen P; Meijer OWM; Daniels LA; van den Bergh RCN; Lont AP; Ettema RH; Oudshoorn FHK; van Leeuwen PJ; van der Poel HG; Donswijk ML; Oprea-Lager DE; Schaake EE; Vis AN
Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282
[TBL] [Abstract][Full Text] [Related]
17.
Fendler WP; Eiber M; Beheshti M; Bomanji J; Ceci F; Cho S; Giesel F; Haberkorn U; Hope TA; Kopka K; Krause BJ; Mottaghy FM; Schöder H; Sunderland J; Wan S; Wester HJ; Fanti S; Herrmann K
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):1014-1024. PubMed ID: 28283702
[TBL] [Abstract][Full Text] [Related]
18. A Multicenter Prospective Clinical Trial of
McCarthy M; Francis R; Tang C; Watts J; Campbell A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
[TBL] [Abstract][Full Text] [Related]
19. How accurate is
Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
[TBL] [Abstract][Full Text] [Related]
20. Advances in prostate-specific membrane antigen PET of prostate cancer.
Bouchelouche K; Choyke PL
Curr Opin Oncol; 2018 May; 30(3):189-196. PubMed ID: 29465429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
